November 23rd 2024
FDA's approval will allow Kedrion to manufacture Ryplazim (plasminogen, human-tvmh), the only FDA-approved therapy for treating PLGD-1, at facility in Bolognana, Italy.
November 19th 2024
It is important to understand the differences between risk-based decision making and other decision making in a pharmaceutical quality system.
Defining and Presenting Overkill Cycle Validation
November 2nd 2013Sterilization validation must be based on a robust, quality-by-design philosophy; autoclave overkill cycles should be validated by correlating lethality data to support chosen critical process parameters, even when using overkill sterilization.